Ikena Oncology Inc.’s plan to launch the first-in-human phase I study with IK-930, a transcriptional enhanced associate domain inhibitor targeting the Hippo pathway in cancer, brought new attention to the Hippo space. The FDA accepted Ikena’s IND application early last month. Now, work with other candidates is picking up steam at a handful of companies pursuing early stage prospects.